DSGN Design Therapeutics, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Design Therapeutics, Inc. (DSGN) SEC EDGAR filings in 2026, including the most recent 10-K annual report filed on March 9, 2026, a 10-Q quarterly report filed on April 28, 2026, an 8-K current report filed on August 3, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Design Therapeutics, Inc. (DSGN) (SEC CIK 1807120), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
Go deeper on Design Therapeutics, Inc.
Ask AI about DSGN filings. Chat with the 10-K, 10-Q, and 8-K for instant answers on financials, risks, and guidance.
Track institutional money. See which funds are building or cutting DSGN positions, quarter over quarter.
Catch cross-signals. Spot when insider buying, fund accumulation, and activist stakes line up on DSGN.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Design Therapeutics, Inc. (DSGN) 8-K current reports disclosing material events.
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Aug 3, 2026 | - | - | - |
8-K | Jun 11, 2026 | - | - | - |
8-K | May 18, 2026 | - | - | |
8-K | Apr 28, 2026 | - | - | - |
10-Q | Apr 28, 2026 | Mar 31, 2026 | - | |
8-K | Apr 1, 2026 | - | - | - |
10-K | Mar 9, 2026 | Dec 31, 2025 | - | |
8-K | Mar 9, 2026 | - | Analysis | - |
8-K | Jan 30, 2026 | - | - | |
10-Q | Nov 5, 2025 | Sep 30, 2025 | - | |
10-Q | Aug 7, 2025 | Jun 30, 2025 | - | |
10-Q | May 7, 2025 | Mar 31, 2025 | - | |
10-K | Mar 10, 2025 | Dec 31, 2024 | - | |
10-Q | Nov 7, 2024 | Sep 30, 2024 | - | |
10-Q | Aug 5, 2024 | Jun 30, 2024 | - | |
10-Q | May 8, 2024 | Mar 31, 2024 | - | |
10-K | Mar 19, 2024 | Dec 31, 2023 | - | |
10-Q | Nov 13, 2023 | Sep 30, 2023 | - | |
10-Q | Aug 14, 2023 | Jun 30, 2023 | - | |
10-Q | May 9, 2023 | Mar 31, 2023 | - | |
SC 13G | Apr 3, 2023 | - | - | |
10-K | Mar 14, 2023 | Dec 31, 2022 | - | |
SC 13G | Feb 8, 2023 | - | - | |
SC 13G | Feb 3, 2023 | - | - | |
SC 13G | Dec 22, 2022 | - | - |
13F Fund Holdings: Quarterly Trend
Latest: Q1 2026Aggregate DSGN share value held by 13F filers tracked by SignalX, by quarter.
- Goldman Sachs Group+234.1K (+86%)
- Dimensional Fund Advisors+133.9K (+45%)
- Renaissance Technologies LLC+121.1K (+42%)
- D.E. Shaw & Co+31.4K (+7%)
- FMR LLC (Fidelity)+27.1K (+4%)
- Citadel Advisors LLC228.4K (-50%)
- Ameriprise Financial123.4K (-78%)
- Millennium Management71.9K (-40%)
- Morgan Stanley45.7K (-7%)
- Two Sigma Investments29.9K (-65%)
- U.S. Bancorp+61
- Vanguard Group Inc−1.63M
- Invesco Ltd−305.8K
- JPMorgan Chase & Co−14.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 153 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe.
Frequently Asked Questions
What are the latest DSGN SEC filings in 2026?
Design Therapeutics, Inc. (DSGN) has filed a 10-K annual report on March 9, 2026, a 10-Q quarterly report on April 28, 2026, an 8-K current report on August 3, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did DSGN file its most recent 10-K annual report?
Design Therapeutics, Inc. (DSGN) filed its most recent 10-K annual report on March 9, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view DSGN 10-Q quarterly reports?
Design Therapeutics, Inc. (DSGN)'s most recent 10-Q quarterly report was filed on April 28, 2026. SignalX displays every DSGN 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has DSGN filed recently?
Design Therapeutics, Inc. (DSGN)'s most recent 8-K was filed on August 3, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find DSGN insider trading activity (Form 4)?
SignalX aggregates every DSGN Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does DSGN file with the SEC?
Design Therapeutics, Inc. (DSGN) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new DSGN filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Design Therapeutics, Inc. (DSGN).
What is DSGN's SEC CIK number?
Design Therapeutics, Inc. (DSGN)'s SEC CIK (Central Index Key) number is 1807120. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1807120 to look up all DSGN filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Stay on top of Design Therapeutics, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 39+ filings.